HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study.

AbstractBACKGROUND:
Clinical studies have shown that interventional lowering of serum free thyroxine (FT4) may be associated with extended survival in patients with some terminal cancers. The report of success with this approach in glioblastoma multiforme caused involvement of the author (A.H.) in the prospective consultative management of 23 end-stage solid tumor patients in whom hypothyroxinemia was induced to prolong life.
PATIENTS AND METHODS:
Patients were self-referred or recommended by attending physicians to the author (A.H.) and had advanced cancers of the brain, ovary, lung, pancreas, salivary gland, and breast or had mesothelioma or soft-tissue sarcoma. Hypothyroxinemia was achieved in euthyroid patients by using methimazole, with the addition of 3,3',5-triiodo-L-thyronine (L-T3) to prevent hypothyroidism and suppress endogenous thyrotropin (TSH). In patients with pre-existent primary hypothyroidism, T3 administration was substituted for T4 replacement. Serum FT4 and TSH concentrations were serially monitored to enable adjustments to drug therapy and prevent clinical hypothyroidism. Survival was measured from the date of hypothyroxinemia induction with T3 or methimazole plus T3. Outcomes were compared with the odds of death based on the Surveillance Epidemiology and End Results and American Joint Committee on Cancer databases and literature reports.
RESULTS:
The survival time of 83% (19 of 23) of patients exceeded the 20% expected 1-year survival for this hypothyroxinemic, end-stage cancer group. The difference between actual and expected survival was significant.
CONCLUSION:
Although this is an uncontrolled observational experience with frank limitations, compassionate medical induction of hypothyroxinemia should be considered for patients with advanced cancers to whom other avenues of treatment are closed.
AuthorsAleck Hercbergs, Rebecca E Johnson, Osnat Ashur-Fabian, David H Garfield, Paul J Davis
JournalThe oncologist (Oncologist) Vol. 20 Issue 1 Pg. 72-6 (Jan 2015) ISSN: 1549-490X [Electronic] England
PMID25410096 (Publication Type: Journal Article)
Copyright©AlphaMed Press.
Chemical References
  • Diazonium Compounds
  • Triiodothyronine
  • Methimazole
  • N-2-diazo-3,3,3-trifluoropropionyl-3,5,3'-triiodothyronine
  • Thyrotropin
  • Thyroxine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Diazonium Compounds (administration & dosage)
  • Female
  • Humans
  • Hypothyroidism (blood, chemically induced, mortality, pathology)
  • Male
  • Methimazole (administration & dosage)
  • Middle Aged
  • Neoplasms (blood, drug therapy, mortality, pathology)
  • Survival Analysis
  • Thyrotropin (blood)
  • Thyroxine (blood)
  • Triiodothyronine (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: